Based on CHD1L’s oncogenic function, inhibition of CHD1L should lead to the inhibition of tumor progression and diminished risk of metastasis. Onconaut is developing first and best-in-class small-molecule therapeutics that target CHD1L.
These therapies when used in combination with standard-of-care treatments are anticipated to result in better patient outcomes and survival across multiple cancers.
Onconaut’s pipeline of >100 designed inhibitors and lead drug candidates targeting CHD1L were developed in the lab of Dr. Dan LaBarbera at the University of Colorado, Anschutz based on the deep comprehension they developed of CHD1L's protein structure, function, and pivotal role in cancer biology.
Using a highly efficient, rapid multi-disciplinary approach to drug discovery that includes automated high throughput and high content screening, in vitro and in vivo lead drug mechanism of action elucidation, comprehensive drug design, medicinal chemistry and pharmacology, the LaBarbera lab identified a pipeline of drug candidates that display antitumor activity alone and synergize with both chemotherapy and targeted therapy in in vitro and in vivo models of cancer.